European approval of niraparib for first-line monotherapy in adults with advanced ovarian cancer

The indication is for use in patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response following platinum-based chemotherapy and is based on data from the PRIMA study.

Source:

PharmaTimes